Dyslipidaemia

Act Now for your ACS Patients

Role of Genetic Testing in Management of Dyslipidemia

Treating to target in clinical practice: Why is it important to achieve recommended LDL-C levels?

Statin/ezetimibe SPC for better adherence to LLT

Prospective evaluation of lipid management following ACS in Saudi Arabia (ACOSYM Study)

Overview of adherence data with LLT highlighting the most recent data with PCSK9i

Metabolic Risk Factors and Effect of Alirocumab on CV Events

Managing the Recurrent ASCVD Risks of Your ACS Patient: A call to Action – GULF Perspective: Part 3

Managing Recurrent ASCVD risk of your ACS Patient: A call to Action – GULF Perspective: Part 2

Managing the Recurrent ASCVD Risks of Your ACS Patient: Gulf Perspective (Part 1)

Lipid management in patients with ACS/ASCVD

Improving Lipid Management for Patients Post-ACS

Identifying and treating patients with high Lipidaemia risk post-ACS

Atherosclerosis: Identifying risks and improving outcomes

Act Now for Your ACS Patients: Treat Aggressively, Combine and Start Early

Act Now for Your ACS Patients: Summary

Act Now for Your ACS Patients: Patient Identification

Single-Pill Combinations in Dyslipidemia

This review describes the potential benefits of combination treatment and presents data supporting the use of single-pill combination (SPC) for increasing exposure to lipid-lowering treatment (LLT).

Public health recommendations for Lp(a) measurement

CV Risk management in T1DM using guidelines

Importance of lipid registries in cardiovascular prevention

Statin/Ezetimibe Combination VS Statin Monotherapy

Evaluation of lipid management following ACS

Event rates and Risk Factors for Recurrent CV Events

ESC Lp(a) in Clinical practice EAS Consensus statement

LDL-C in the management of high cardiovascular risk, changing the paradigm for prevention

The European experience: Swedeheart and AIFA registries

Highlights on the most recent real-world data on the use of PCSK9 inhibitors, including those from the Swedeheart and AIFA registries.

Why compromise for less: Should PCSK9 inhibitors be initial therapy?

What do us physicians and patients think about LLTs and goals of treatment?

Physician and patient perceptions of benefits, risks, and treatment goals of lipid-lowering therapy: Results from GOULD registry.

APSC Consensus Recommendations on Dyslipidemia

Acute LDL-C Reduction Post ACS: Strike Early and Strike Strong: From Evidence to Clinical Practice

Use of Lipid-Lowering Therapies Over 2 Years

Prescription patterns of lipidlowering therapies over time in patients with atherosclerotic cardiovascular disease: Findings from Gould study

Should we encourage earlier and broader use of combination therapies in dyslipidemia?

Prospective evaluation of lipid management following acute coronary syndrome in Saudi Arabia

Relationship Between LDL-C LLTs and Risk of Stroke

Possible Challenges Post One Year of ESC/EAS Guidelines

Perceptions and Barriers on the use of PCSK9 inhibitors

Prognostic impact of achieving LDL cholesterol guidelines

Cardiovascular Disease in Saudi Arabia: Facts and the Way Forward

PCSK9 inhibitors and ACS

PCSK9 Inhibitors in Cardiovascular Disease

PCSK9i and Prevention of CVD

The synopsis of a Cochrane Systematic review on PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.

PCSK9 Inhibitors in Real World Practice

PCSK9i after hospital discharge for acute MI

Factors associated with time to PCSK9i initiation following hospital discharge for acute myocardial infarction.

ACC/AHA vs ESC/EAS LDL–C recommendations for residual risk reduction in ASCVD: A simulation study from Da Vinci

Approach for Patients with CAD: Focus on LDL-C Control

Approach for Patients with PAD and T2D: Focus on LDL-C Control

Act Now for Your ACS Patients: Optimize Your ACS Pathway